Fiscal Year Ending March 2026 Third Quarter Financial Summary [Japanese GAAP] (Consolidated)

Performance Overview

In the consolidated cumulative third quarter of the fiscal year ending March 2026, net sales were 73.6888 billion yen, a 1.3% decrease compared to the same period last year. However, operating income increased 21.6% to 12.937 billion yen, ordinary income rose 24.9% to 14.619 billion yen, and net income attributable to owners of the parent for the quarter was up 34.0% at 10.64 billion yen. The Basic Chemicals segment saw a 9.7% increase in net sales due to resolution of supply issues and improvement in overseas market conditions, while the Functional Chemicals segment declined by 10.9% due to reduced demand for some products. The Healthcare segment grew 5.1% driven by increased demand for pharmaceutical purification materials. The Trading and Other segment decreased 12.4% due to lower sales.

Financial Position and Future Outlook

Total assets increased 5.9% from the end of the previous fiscal year to 162.974 billion yen, and net assets rose 6.4% to 122.952 billion yen, maintaining a stable financial base with an equity ratio of 75.4%. There is no revision to the full-year earnings forecast for the fiscal year ending March 2026, with expected net sales of 102.0 billion yen (up 5.8% YoY), operating income of 17.3 billion yen (up 30.6% YoY), and net income attributable to owners of the parent of 13.5 billion yen (up 30.7% YoY). Earnings per share, considering the impact of stock splits, is projected at 84.92 yen.